(OTC Stock Symbol MYCOF). This is my next stock that looks ready to move in a
major way, so make sure you have it pulled up on your trading screen Monday morning
at the opening bell.
Mydecine Innovations Group is a life sciences company dedicated to the development
and commercialization of adaptive pathway medicines, natural health products and
digital health solutions.
Mydecine experienced cross functional teams have the capabilities to oversee all areas of
drug development including synthesis, drug delivery system development, clinical trial
execution, through to product commercialization and marketing.
By leveraging strategic partnerships with scientific, medical, military, and clinical
organizations Mydecine is at the forefront of the efficient development of psychedelic
derived medicines and therapeutic solutions.
Their trailblazing portfolio of companies is focused on providing innovative and
effective treatment options that can help millions of people live healthier lives.
Mydecine Innovations Group Inc. is a parent company which operates innovative
product divisions in the Naturally Sourced Therapies (NST) space.
Mydecine Innovations Group Inc. operates a number of hemp-derived CBD and
psilocybin brands that design, manufacture and distribute cutting edge products.
Mydecine Innovations Group Inc. further enhances their portfolio with cultivation
properties, land assets and retail space.
Mydecine Signs Partnership Agreement With Applied Pharmaceutical Innovation
Mydecine Innovations Group Inc. announced the establishment of a research division
agreement with Applied Pharmaceutical Innovation (“API”), a translational commercial
drug development institute hosted in the University of Alberta’s Faculty of Pharmacy and
The agreement with API provides exceptional capacity for Mydecine and the ability to
significantly speed their product development with leading experts in the pharmaceutical
sciences and established drug development facilities.
SIGN UP FOR OTC TIP REPORTER NEWSLETTER
The Faculty of Pharmacy and Pharmaceutical Sciences is consistently ranked in the top
15 globally for the citations of research by international QS rankings in pharmacy and
pharmacology and includes a wide range of experts from discovery, pharmaceutical
analysis, drug action, disposition, formulation and clinical development.
Mydecine is also able to access broader expertise through the agreement such as API’s
collaborating institute the Alberta Machine Intelligence Institute (Amii) – ranked among
the top 5 institutes in the world for AI/ML – as well as experts in mycology,
pharmacometrics, neuropharmacology and much more at universities throughout the
Through the agreement, Mydecine has the ability to immediately commence fungal
discovery investigations with varietal mushrooms and their extracts, including scheduled
With access to GMP capacity and Health Canada licenses that include the ability to move
to import and export, conduct R&D, and clinical trials Mydecine is able to begin work
that will take other companies years to establish the capability for. Research and
development is commencing with a significant program to extract, analyze, and
determine the effects of various compounds from fungi and their pharmacokinetic
disposition and development of dosage forms for specific indications, providing
Mydecine with an extensive assets and capacity to become a leader in the space.
The end goal is developing products with clinical applications over a period of three
“We see this agreement as a core component of our work as a company,” says Mydedine
CEO Josh Bartch “the API team at the Faculty of Pharmacy and Pharmaceutical Sciences
gives us the ability to rocket our product development ahead by years, providing the
know-how, facilities, and licenses to quickly establish Mydecine as a leader in naturally
sourced therapies for a wide variety of indications. The research division also provides a
phenomenal synergy with our other recent acquisitions, giving us a dedicated team to
explore myco-inspired treatments particularly for areas of high need such as mental
“Our partnership with the University of Alberta will unlock brand new avenues for the
study of medical uses of mushrooms,” Robert Roscow, CSO of Mydecine. “This
partnership is a fundamental aspect of Mydecine’s expanding unique research network.
We are investigating the potential of mushrooms and their compounds to improve
human health and wellness.
This research partnership opens up, not only investigation of single molecules from
mushrooms but also more complex formulations. The breadth of research resources at the
University of Alberta, from world class AI to cultivation and pharmacology, as well as
their possession of Health Canada License allows an unprecedented level of study.”
“Back to the fungal future,” Dr. Neal Davies, Dean, Faculty of Pharmacy and
Pharmaceutical Sciences “Pharmaceutical activity of fungal metabolites have been
known for at least 15 centuries and contemporary research has discovered some novel
molecule leads for unique mycological medications for nature inspired treatments in the
new millennium. This bodes very well for the program developing promising treatments.”
“We’re thrilled to be working with Mydecine,” says API CEO, Andrew MacIsaac,
“we see their focus as one of growing importance and high potential that will serve them
well. By developing a world class R&D program that discovers potential new lead
compounds, synergistic effects, and increased therapeutic indications for
mushroom-derived products, Mydecine will stand out in this bourgeoning sector.
Mydecine Drops Bombshell Acquisition News Their Acquiring Mindleap Health’s
Advanced Digital Telehealth Platform
MYCOF Just Released Blockbuster Acquisition News They Have Signed a Definitive
agreement with Mindleap Health Inc. (“Mindleap”) for the acquisition of a 100% interest
in MindLeap’s Digital Telehealth Platform focused on the emerging psychedelics
Mindleap Health we are focused on positively impacting society through a disruptive
platform for psychedelic aftercare and by developing new forms of medicine.
Advanced Digital Telehealth Platform Technology
Mindleap is a digital health platform that helps people connect with mental health
specialists that can empower them to thrive and develop habits for a healthy mind.
Online mental healthcare brings convenience, improves access to treatments and can
lead to more personal breakthroughs. Mindleap’s proprietary platform is designed by
clinical psychologists and neuroscientists to provide professional support and
personalized treatment for every person.
The Mindleap platform will provide support for people that are looking to achieve
personal transformations and overcome mental health challenges. Mindleap is the only
digital health platform that combines telehealth with mood, emotion and habit tracking.
Mental health has been a big issue and is a major focus for the Mydecine Group of
companies. Currently the World Health Organization estimates that there are more than
450 million people suffer from mental health disorders worldwide placing mental
disorders among the leading causes of ill-health and disability worldwide. The US has the
highest prevalence of mental health disorders in the world with 27 percent of adults, yet
only 41 percent of the people who had a mental disorder in the past year received
professional health care or other mental health services due to convenience and cost
Mydecine Director and CEO, Josh Bartch, stated: "This acquisition brings Mydecine an
elite team drawn from tech, mental health, and science, paired with innovative
technology with a strong USP and large addressable market. The scalability of the
platform means high potential return on investment especially given Mindleap's 1st
mover advantage in the rapidly emerging psychedelic medicine sector."
Mindleap is focused on making a considerable difference in people's lives by improving
access to mental health services and providing more personalized and effective treatments
utilizing the latest technology. The Mindleap Platform upon launch will provide:
- Convenient and more affordable access to mental health services
- Psychedelic aftercare, addiction, and holistic wellness services
- On Demand access to mental health programs
- Automated appointment booking and international payments
- Secure and confidential video sessions
- Critical tools for improved outcomes and personalized care
- Easy to use software with fast learning curve for specialists
- Secured encrypted system that is HIPAA and GDPR compliant
- High engagement features and gamification that improve user experience
The team of mental health professionals that led the product design at Mindleap comprise
of four PHD's including leading neuroscientists, psychotherapists, and clinical
Mindleap's CTO Simon Abou-Antoun has 10+ years of technical leadership, managing
large projects and developing custom solutions for companies including Amazon,
Scotia Bank and Fiat Chrysler. Simon commented: "We have gathered a strong team with
different sets of skills ranging from software developers, UX/UI designers and IOS and
Android experts. Our full stack, frontend, backend, Cloud and QA specialists are
currently focused on ensuring all requirements are met so we can launch Mindleap
by the end of summer."
Mindleap's founder and CEO Nikolai Vassev brings a unique skillset to the company as
he has proven experience driving top line software licensing and SAAS revenue into
some of the largest organizations in the world. During his career he has sold millions of
dollars worth of cybersecurity and data analytics solutions and understands the intricacies
of successfully implementing software solutions that are bringing value to customers,
partners, and end users. Nikolai will be representing Mindleap and Mydecine at the
"Investing in Psychedelics" event put together by the Canadian Securities Exchange,
and CFN Media along with other industry executives and experts. You can register to
attend for free here and can tune in on June 17 starting at 12:00pm PDT.
Nikolai Vassev, Mindleap Founder and CEO commented: "The intense anxiety and fear
that many people are feeling has led to social instabilities as the virus crisis and
economic collapse continues to worsen and compound already existing problems.
Mindleap's platform is set to launch in a few short months and will provide much
needed support to those people suffering from depression, addiction and other mental
About Mydecine Innovations Group
Mydecine Innovation's Group is a life sciences company focused on the development
and commercialization of products and services that contribute to improving overall
health and wellbeing. The company's mission is to create a healthier world through
advanced technologies, natural products, and psychedelic derived medicines.
Mydecine Innovations Group owns a group of trailblazing companies that are focused on
helping millions of people live better lives and our portfolio includes:
- Cannabis & Fungi Based Products
- Mycology Research & Development
- Disruptive Technology
- Therapeutic Treatment Facilities
- Large-Scale Distribution
- Psychedelic-Derived Medicines
About Mindleap Health
Mindleap Health is developing an advanced digital telehealth platform that will provide
support for people that are looking to achieve personal transformations and overcome
mental health challenges. MindLeap is the only digital telehealth platform that combines
telemedicine with mood, emotion, and habit tracking. This is a paradigm shift to
conventional mental health as Mindleap personalized support and users have the tools
needed to track their progress and take control of their mental health.
Mindleap Health is at the forefront of this industry with its digital telehealth platform
focused on the psychedelic therapy industry. Mindleap has recognized that there is an
unmet need for people to access psychedelic integration specialists and is creating the
world’s first platform focusing on psychedelic aftercare.
The tools Mindleap is building are the first of their kind to allow the patient to monitor,
record, and track their mood and habits (both positive and negative) along with providing
access to modern health services, namely integrated coaching to translate psychedelic
experiences into positive change.
The system is completely secure and compliant with HIPAA and GDPR mandates and is
being developed by a world-class development team with a proven track record.
Finally, Digital Mental Healthcare
As a society, we are becoming more familiar with digital healthcare. Electronic medical
records are now the norm. The Covid-19 pandemic has resulted in more usage of video
visits to doctors as people sheltered in place to prevent virus spread. A crisis being a
catalyst is certainly unfortunate, but it did just make e-visits more mainstream as doctors
and patients alike embraced social distancing.
Apropos, already valued at $31.46BIL in 2018, the global telemedicine market is
expected to grow at a 19.3% rate by 2025, indicating that adoption is only going to keep
Mindleap's comprehensive platform, expected to launch at the end of summer, includes
video visits, appointment scheduling and payment solutions.
Mindleap is also capitalizing on the world’s love of digital technologies, such as
smartphones and connected wearable devices, in a newer science dubbed digital
phenotyping. By passively collecting data (e.g. sleep patterns, exercise, social patterns),
outcomes can be predicted using Artificial Intelligence and Machine Learning.
This information subsequently helps healthcare providers optimize support.
It is the epitome of the purpose of Big Data to anonymously help the greater cause by
aggregating massive amounts of info. It’s very valuable from both financial and
The market opportunity as a first mover is tremendous, to say the least. There are more
than 577,000 mental health professionals and over 13,000 behavioral health clinics in the
U.S. to treat the more than 45 MIL Americans that have a mental illness.
To put this market opportunity into perspective, consider Livongo. The company has
made a splash on Wall Street ($7.4BIL market cap) with an application connecting
diabetics to physicians with the strategy that better engagement will promote better
health. There are fewer diabetics (~34 MIL) in the U.S. than people with mental illness.
We're at a Tipping Point
Thankfully, awareness is growing about the very real medicinal usefulness of psilocybin
and other psychedelics. Indeed, they remain illegal as Schedule I drugs currently, but
positions are beginning to soften to encourage clinical research. Oakland and Denver
have already decriminalized magic mushrooms and over 100 other cities are considering
Leading research organizations, including Johns Hopkins, have dedicated millions of
dollars to study psychedelics, which will only help create tailwinds with every positive
The next logical progression is providing patients with the best support possible to help
them achieve meaningful changes to their quality of life. That’s exactly what Mindleap
Health – and now Mydecine Innovations Group – is bringing to the table by changing the
shape of the aftercare model.
Big Names are Investing in Psychedelics (Should You?)
If you’re still on the fence about psychedelics, however, you need to know that there are
some very big names in the business. Some, like cannabis guru Bruce Linton, see the
same early regulatory signs and support that medicinal cannabis received. Others, like
Canadian businessman Kevin O’Leary, are investing in psychedelics after passing on
Both Linton and O’Leary recently became heavy investors in Mind Medicine Inc., a
private Canadian neuro-pharmaceutical company aiming to develop drugs with the same
mental health benefits but without the associated high. They’re joined by James Bailey,
a partner at the private equity firm Bail Capital that has invested heavily in the industry.
Another name that should be familiar to investors is Peter Thiel, the Silicon Valley
billionaire that co-founded PayPal and sits on the board for Facebook Inc. Thiel is a
heavy investor in psychedelics. He’s joined in the venture by investing in a German
biotech start-up with a lot of venture capital support looking to fund more research on
psilocybin, MDMA, and other psychedelic drugs.
A major driving force in the psychedelics wave isn’t a name, however, it’s a government
organization. The US Food and Drug Administration (FDA) has been impressively
receptive to psychedelics in recent years, starting in 2017 when it granted Breakthrough
Therapy Designation to MDMA-assisted psychotherapy. Since then it has expanded the
number of companies allowed to research the drugs, and in March of this year granted
approval for a ketamine-related depression drug from Johnson & Johnson.
Leading research organizations, including Johns Hopkins, have dedicated millions of
dollars to study psychedelics, which will only help create tailwinds with every positive
As the emerging sector sees more trials and investments, you can expect more big names
to enter the psychedelics playing field. With cannabis acting as a roadmap and helping to
shift public opinion towards previously illicit drugs, and with a pure medicinal focus
helping propel the industry, it’s looking like psychedelics are the real deal.